MedPath

The exploratory study on change of the gutmicrobiota in Rabeprazole divided doses:Direction crossover controlled trial in front of an open label

Not Applicable
Conditions
Reflux esophagitis.
Registration Number
JPRN-UMIN000032040
Lead Sponsor
Shiga University of Medical Science
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
12
Inclusion Criteria

Not provided

Exclusion Criteria

1.No consent 2.With the drug including a suppressant acid-secreting for the past one month. 3.With probiotics (medicine for intestinal disorders) or the antimicrobial agent for the past one month. 4.With grapefruits for the past two weeks. 5.With operating treatment for upper gastrointestinal disease including esophagus and stomach. 6.During pregnancy or nursing.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Correlation of intragastric pH and enteric bacteria profile.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath